FDA gives RBI Fast Track status for Alzheimer's stem cell therapy

Regeneration Biomedical said the FDA has granted Fast Track designation to its direct-to-brain stem cell therapy for Alzheimer’s disease after a Phase I study showed safety and biomarker improvements in six patients. The company has also cleared a randomized Phase II trial that will test repeated treatment over one year. Why it matters: - FDA Fast Track status can speed development and review for therapies aimed at serious diseases with unmet medical need. - The designation gives Regeneration Biomedical more frequent FDA interactions as it advances a direct-to-brain stem cell approach for Alzheimer’s disease. - RBI said the FDA decision also validates its strategy of bypassing the blood-brain barrier with autologous stem cells. What happened: - The FDA granted Fast Track designation to Regeneration Biomedical’s investigational stem cell therapy for Alzheimer’s disease. - The decision followed RBI’s FDA-cleared Phase I trial in six patients with mild-to-moderate Alzheimer’s disease. - RBI also said the FDA cleared a multi-center, randomized, double-blind, placebo-controlled Phase II trial. The details: - The Phase I study used a single intracerebroventricular administration of Wnt-activated adipose-derived stem cells. - The treatment was delivered directly into the brain. - RBI reported no treatment-related serious adverse events in the Phase I study. - The study also showed sustained improvements in cerebrospinal fluid biomarkers tied to Alzheimer’s disease. - Those biomarkers included amyloid beta, phosphorylated tau, total tau and histone markers. - RBI said exploratory cognitive improvements were also seen after one administration. - The Phase II trial will test repeated intracerebroventricular dosing every two months for one year. - RBI said the FDA cleared the study to examine whether repeated treatment can alter the course of Alzheimer’s disease. - RBI presented the Phase I findings at the 2026 Annual Meeting of the International Society for Cell & Gene Therapy in Dublin, Ireland. - At that meeting, the company reported sustained improvements in CSF proteomic markers and exploratory cognitive outcomes. Between the lines: - The Fast Track designation does not mean the therapy is approved, but it can help move a program with early signals through development faster. - RBI said it is among the first organizations to receive FDA Fast Track designation for an autologous stem cell therapy delivered directly to the brain for Alzheimer’s disease. - Christopher Duma, RBI’s founder and president, said the designation is meaningful validation of the Phase I findings and the company’s whole-brain treatment concept. What’s next: - RBI will move ahead with the Phase II placebo-controlled study. - The trial will test whether repeated direct-to-brain stem cell treatment can provide a stronger and more durable effect than a single dose. - RBI’s broader platform also includes research in other neurodegenerative disorders. The bottom line: - RBI now has an FDA development boost and a follow-on trial path for a high-risk Alzheimer’s program that has shown early safety and biomarker signals.